ISRCTN69908361 https://doi.org/10.1186/ISRCTN69908361

Intramuscular depomedrone in very early inflammatory polyarthritis

Submission date	Recruitment status	[X] Prospectively registered
05/02/2002	No longer recruiting	[_] Protocol
Registration date	**Overall study status**	[_] Statistical analysis plan
05/02/2002	Completed	[X] Results
Last Edited	**Condition category**	[_] Individual participant data
23/08/2011	Musculoskeletal Diseases	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Deborah Symmons

Contact details
ARC Epidemiology Unit
University of Manchester
Manchester
United Kingdom
M13 9PT
+44 (0)161 275 5037
deborah.symmons@fs1.ser.man.ac.uk

Additional identifiers

Protocol serial number
S0671

Study information

Scientific Title

Acronym

STIVEA

Study objectives
That treating patients with very early inflammatory polyarthritis (less than 10 weeks duration) with a three week course of IM steroid will prevent a substantial proportion of cases from evolving into rheumatoid arthritis.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised placebo controlled trial

Primary study design
Interventional

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Inflammatory polyarthritis

Interventions
Patients will be randomised to receive:
1. Either weekly injections of 80 mg depomedrone (methylprednisolone) deep into the gluteal muscles for 3 weeks
2. Placebo

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
Depomedrone (active ingredient: methylprednisolone)

Primary outcome(s)
The need to start second-line drug therapy (e.g. methotrexate, sulphasalazine) by the 6 month assessment.

Key secondary outcome(s))
1. Whether the patient has satisfied classification criteria for rheumatoid arthritis
2. The presence of radiological erosions in the hands or feet at 12 months
3. The change in physical disability and clinical diagnosis

Completion date

01/06/2006

Eligibility

Key inclusion criteria
Patients aged 18 years or more with inflammatory polyarthritis with a duration of 4 - 10 weeks.

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Adult

Lower age limit
18 years

Sex
All

Key exclusion criteria
Does not match inclusion criteria

Date of first enrolment
01/06/2003

Date of final enrolment
01/06/2006

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
ARC Epidemiology Unit
Manchester
United Kingdom
M13 9PT

Sponsor information

Organisation
Arthritis Research Campaign (ARC) (UK)

ROR
https://ror.org/02jkpm469

Funder(s)

Funder type
Charity

Funder Name
Arthritis Research Campaign (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/03/2010		Yes	No